Imaging multiple myeloma: Vij and colleagues provide a concise review of the present status and promising developments in multiple myeloma, including new molecular imaging biomarkers.
Page 1
EXINI quantitative BSI: Larson offers perspective on an article in the current issue of JNM focusing on an improved and more accurate computerized bone scan index calculation that mimics but outperforms manual approaches.
Page 5
Coagulation factor and theranostics: Urbain provides background for and previews an article in this issue of JNM on a novel approach for tagging, visualizing, and quantifying tissue factor expression at the surface of cancer cells using a radiolabeled agent.
Page 7
68Ga-BBN PET/CT in glioma: Zhang and colleagues report on the safety, biodistribution, and radiation dosimetry of a gastrin-releasing peptide receptor–targeting, 68Ga-labeled bombesin peptide–derivative PET tracer in healthy volunteers and assess receptor expression levels in glioma patients.
Page 9
Lung nodules missed by PET/MR: Sawicki and colleagues report on a study evaluating outcomes in patients with small lung nodules missed by 18F-FDG PET/MR imaging and discuss the implications for clinical practice.
Page 15
PET/MR vs. PET/CT in NSCLC: Huellner and colleagues compare the diagnostic accuracy of whole-body unenhanced PET/MR with that of PET/CT in TNM staging of non–small cell lung cancer.
Page 21
68Ga-HER2-nanobody PET/CT trial: Keyaerts and colleagues describe phase 1 studies of the safety, biodistribution, dosimetry, and PET/CT tumor-targeting potential of a 68Ga-labeled anti–human epidermal growth factor receptor 2 nanobody in women with primary or metastatic breast carcinoma.
Page 27
68Ga-DOTATATE PET in NETs: Skoura and colleagues detail the results of the first 8 years of data from a large study of 68Ga-DOTATATE PET/CT in neuroendocrine tumor management and the effect of imaging results on treatment and survival.
Page 34
Analytic validation of BSI: Anand and colleagues report on a series of analytic validation studies to evaluate the performance of an automated bone scan index as a reproducible and quantitative imaging biomarker in patients with metastatic prostate cancer.
Page 41
18F-DCFBC PET/CT in metastatic prostate cancer: Rowe and colleagues examine the potential of this first-in-class radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen for detecting metastatic hormone-naïve and castration-resistant prostate cancer.
Page 46
Motion-corrected 18F-NaF PET: Rubeaux and colleagues explore motion correction in gated 18F-NaF PET as a way to enhance image quality and improve uptake estimates in the assessment of vulnerable coronary artery plaques.
Page 54
Differential diagnosis of parkinsonism: Tripathi and colleagues validate a probabilistic algorithm to classify subjects with clinical parkinsonism but uncertain diagnosis, based on expression of metabolic covariance patterns for idiopathic Parkinson disease, multiple-system atrophy, and progressive supranuclear palsy.
Page 60
18F-FSPG PET in inflammation: Chae and colleagues explore 
transporter activity and the detection of inflammatory or infectious lesions with this l-glutamate–derivative PET agent that is specifically taken up by the 
cysteine/glutamate system.
Page 67
Cohesive protocol for pediatric PET/MR: Klenk and colleagues research the question of whether administration of gadolinium chelates is necessary for accurate characterization of pediatric tumors on 18F-FDG PET/MR images.
Page 70
PSF modeling in PET/MR: Aklan and colleagues assess the quantitative and qualitative impact of inclusion of point-spread function modeling in the process of iterative PET image reconstruction in integrated PET/MR imaging.
Page 78
SUVpeak in lung cancer: Laffon and colleagues compare average SUVpeak in a circumscribed volume in an 18F-FDG–positive lesion with an SUV computed from the 40 hottest voxels throughout the lesion to determine which identifies the most metabolically active areas.
Page 85
Quantitative PET TF imaging: Nielsen and colleagues report on development of a novel PET tracer for specific imaging of tissue factor expression, which is upregulated in many solid tumors, using an 18F-labeled derivative of factor VII.
Page 89
PET/CT and CD30-positive lymphoma: Rylova and colleagues describe the results of translational studies with 89Zr-DFO-AC-10, a sensitive PET agent with high tumor-to-normal tissue contrast and promise for imaging in patients with lymphomas and other CD30-expressing diseases.
Page 96
124I PET and 131I SPECT detectability: Beijst and colleagues investigate whether reported discrepancies between 124I PET/CT and 131I SPECT/CT in 131I therapy may be ascribed to a difference in lesion detectability related to sufficient administered 124I activity.
Page 103
PET imaging of copper trafficking: Torres and colleagues describe brain copper trafficking in a transgenic mouse model of Alzheimer disease using PET imaging with 64Cu, to determine its potential as a diagnostic biomarker of the disorder.
Page 109
11C-DASB and SERT imaging: Walker and colleagues assess the feasibility of using 11C-DASB, a serotonin transporter ligand, for reproducible quantification of serotonin transporter density and affinity in vivo in rats and mice.
Page 115
Uncertainty and absorbed dose: Spielmann and colleagues detail the development of an uncertainty analysis method and its use in calculating uncertainty in internal doses of 7 common radiopharmaceuticals.
Page 122
Troglitazone and cancer cell glycolysis: Moon and colleagues evaluate the way in which troglitazone influences cancer cell glucose metabolism and uptake of 18F-FDG and investigate its molecular mechanism in relation to anticancer effects.
Page 129
MR-based pseudo-CT synthesis for PET/MR: Torrado-Carvajal and colleagues describe a methodology for synthesizing a pseudo-CT volume from a single T1-weighted volume, facilitating creation of attenuation correction maps for PET/MR.
Page 136
Consensus report on fluorescence guidance: Rosenthal and authors from the International Society of Image Guided Surgery critically evaluate imaging technology and agents for fluorescence-guided oncologic surgery and make recommendations for clinical trial development.
Page 144
EANM/MIRD Pamphlet 26: Ljungberg and colleagues from the SNMMI Medical Internal Radiation Dose Committee and the European Association of Nuclear Medicine present the latest in a series of isotope-specific guidelines, here focusing on 177Lu and applications in radiopharmaceutical therapy.
Page 151
- © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.